GenSight Biologics Raises EUR3 Million via Share Placing, Subscription

03:29 AM EST, 12/29/2025 (MT Newswires) -- GenSight Biologics (SIGHT.PA) said Monday it raised 2.9 million euros through a placing and subscription of shares with existing shareholders Heights Capital, Invus, and Alumni Capital. The fundraising comprised the issue of 30,433,950 ordinary shares with a par value of 0.025 euro per share, alongside 6,571,428 pre-funded warrants exercisable into an equal number of ordinary shares. Additionally, it included 37,005,378 warrants giving the right to subscribe for a further 37,005,378 ordinary shares. The biopharma company said it plans to use 73% of the net proceeds to advance the development of its GS010/LUMEVOQ candidate, including funding related cash requirements. The remaining proceeds will be used to finance a 700,000-euro redemption payment on its convertible bonds.